Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Atacama Labs Oy

This article was originally published in Start Up

Executive Summary

Atacama Labs aims to create better oral solid-dosage forms using a pneumatic dry granulation process that it claims can granulate virtually any active drug ingredient. To prove the worth of its technology to potential clients, Atacama has applied its method to two drugs that are notoriously difficult to dry-formulate: paracetamol for pain and metformin for diabetes. That mission has been accomplished, and now Atacama is inviting drug companies to send it proprietary compounds that they deem their most difficult to formulate.

Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts